Revive Therapeutics Enters Exclusive License For Ganoderma Lucidum Intellectual Property

Revive Therapeutics (CSE: RVV) last night announced that it has has entered into an exclusive licensing agreement. The licensing agreement pertains to IP related to compounds of Ganoderma Lucidum, a form of a medicinal mushroom that has been found to have anticancer properties by the St. Jude Children’s Research Hospital.

The IP itself has been licensed from the Peurto Rico Science Technology and Research Trust, whom represents both St. Jude’s as well as Universidad Central del Caribe as it pertains to the licensing of intellectual property. Researchers from both the University and St. Jude’s worked together to discovery that compounds of the Ganoderma lucidum mushroom reportedly contain anti-cancer activity, which is said to been especially significant against forms of breast cancer.

Intellectual property licensed under the arrangement is held within an international patent, entitled “Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization.” Revive has gained the exclusive worldwide development and commercial rights related to the IP.

Nord Precious Metals — sponsored Sponsored · Nord Precious Metals

Ganoderma lucidum is a mushroom that has been used for millenia within traditional medicine. More recently, an extract of the mushroom that is commercially available is reportedly used in the prevention and treatment of cancer, immunological disorders and hypertension, with further ongoing researching presently suggesting it reduces the viability of breast cancer, while reducing tumor sizes by up to 50%, among other factors.

“We are very excited about the new addition to our clinical-stage product pipeline as part of our long-term strategy of unlocking the therapeutic potential of medicinal mushrooms such as psilocybin and Ganoderma lucidum to treat mental health, substance abuse and aggressive cancers. Our intention is to build off from the research conducted at St. Jude Children’s Research Hospital and UCC by advancing towards FDA IND-enabling studies to allow for human clinical studies.”

Michael Frank, CEO

Revive Therapeutics last traded at $0.42 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a former client of Canacom Group, the parent company of The Deep Dive. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Questcorp Begins 600 Metre Phase 2B Drill Program at La Union

Selkirk Copper Wraps 54,579 Metre Phase 2 Program at Minto, Hits 5.97% Copper Equivalent

Related News

Growing Medical Acceptance of Psychedelics – The Daily Dive feat Derek Welsh of Revive Therapeutics

For our final episode of The Daily Dive this week, host Cassandra Leah is joined...

Friday, December 4, 2020, 01:00:00 PM

Revive Therapeutics Appoints Airway Disease Expert As Advisor For COVID-19 Phase 3 Study

Revive Therapeutics (CSE: RVV) has strengthened its scientific and advisory team as it looks to...

Thursday, December 31, 2020, 07:39:28 AM

Revive Therapeutics And The Psychedelic Revolution

A massive psychedelics boom is already here. In fact, with the potential to treat a wide...

Sunday, June 21, 2020, 10:30:00 AM

Revive Therapeutics Partners With UCSF To Study Bucillamine For Severe COVID-19

Revive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered...

Monday, May 3, 2021, 09:24:15 AM

Havn Life to Supply Revive Therapeutics With Psychedelic Compounds

This morning Revive Therapeutics (CSE: RVV) announced they have signed a supply agreement with Havn...

Tuesday, October 20, 2020, 10:16:16 AM